Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemigatinib in Advanced GI Cancer with FGFR Alterations
NCT05559775Phase 2Unknown
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Aug 2022
- Primary completion
- Aug 2024
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of pemigatinib in gastrointestinal cancer, sponsored by Zhejiang Cancer Hospital. Status: unknown.
02
Drugs
pemigatinib
03
Conditions
gastrointestinal cancer
Beyond the preview
Go deeper on NCT05559775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05559775.